Last reviewed · How we verify
NCT03583021
Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Male
NA trial testing Sugammadex Injectable Product in Gallbladder Diseases in 42 participants. Completed in 31 December 2018.
31 October 2018
Quick facts
| Lead sponsor | Ajou University School of Medicine |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 42 |
| Start date | 25 June 2018 |
| Primary completion | 31 October 2018 |
| Estimated completion | 31 December 2018 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Sugammadex Injectable Product — full drug profile →
- Neostigmine Injectable Product — full drug profile →
Conditions studied
- Gallbladder Diseases — all drugs for Gallbladder Diseases →
Sponsor
Ajou University School of Medicine
Who can join
Adults 65 to 80, male only, with Gallbladder Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in male patients who are reversed with sugammadex or neostigmine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03583021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sugammadex Injectable Product
Trials testing the same drug.
- NCT04407078 — Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Female · NA · completed
Other Ajou University School of Medicine trials
Trials by the same sponsor.
- NCT07101380 — Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients · NA · recruiting
- NCT07395752 — Youth Suicide and Self-Harm Intervention: Clinical and Biological Outcomes Study · NA · recruiting
- NCT06964217 — Immediate Fracture Risk After Antihypertensive Drug Initiation · not yet recruiting
- NCT05751603 — Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex · NA · not yet recruiting
- NCT07479160 — Heart to Heart Web-based Communication Program for Heart Failure · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03583021 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ajou University School of Medicine
- Last refreshed: 29 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03583021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing